The third phase of a clinical study of mRNA-1273, which Moderna wants to market worldwide as a vaccine against covid-19, involves 30,000 people. Half of them received the vaccine, the other half were control and therefore received only placebo. So far, covidem-19 disease has been demonstrated in 95 study participants. Only five of them belong to the vaccinated group, the remaining 90 cases were found in the control group.
Moderna calculated the effectiveness of her product at 94.5 percent. The data refer to the extent to which the vaccine can prevent the onset of the disease. Data to show how it can prevent coronavirus infection are not yet available. For full-time immunization, Moderna, like its competitors, requires two doses.
–
According to Moderna, the main side effects of the substance include fatigue, muscle pain and pain at the injection site.
The European Commission is negotiating with the American concern Moderna to supply up to 160 million vaccination doses.
Which will be the best?
One week ago, the American company Pfizer and the German company BioNTech announced that their vaccine was 90% effective. At that time, the report significantly affected the stock markets. Pfizer and BioNTech are being tested on 43,500 people. The Russian authorities also announced last week that the Sputnik V vaccine is 92 percent effective. At the same time, Russian Health Minister Mikhail Muraško announced the start of mass production of this vaccine.
Europe is looking for a vaccine
The European Medicines Agency (EMA) announced on Monday that it has launched a preliminary examination of Moderna’s application to register its product on the European Union market. The so-called rolling review, announced by the EMA, makes it possible to speed up the process of registering promising drugs and vaccines. In this type of procedure, the EMA is now also investigating Pfizer and AstraZeneca vaccines. It will only be possible to register substances once the EMA has sufficient evidence of their efficacy, quality and safety. The advantage is that the study can be started before the end of the third phase of the clinical study and pharmaceutical companies can supply the data gradually.
–
Moderna wants to request emergency use of the vaccine in the US and other countries in the coming weeks. If approved, it wants to deliver about 20 million doses to the US market by the end of the year.
The competition is fierce
According to the World Health Organization (WHO), 47 candidate vaccines against covid-19 were in clinical trials earlier this month and 155 vaccines are in preclinical testing. In the last, third phase of clinical trials, the WHO lists 11 vaccines.
– .
